Form 4: Labcorp EVP reports performance award vesting

Megan D. Bailey acquired 1,184 shares from a vested performance award; 481 shares were withheld for taxes at $268.38, increasing her direct holdings to 4,851.

Summary

• Megan D. Bailey (EVP, President, Central Labs & International) reported equity transactions in Labcorp Holdings Inc. (LH) on 2026-03-26.
• 1,184 common shares were acquired at $0 from a performance award granted on 2023-02-07 tied to the 2023–2025 performance period ending 2025-12-31.
• 481 shares were disposed of via tax withholding at $268.38 per share.
• Net increase in directly owned shares: 703, bringing direct ownership to 4,851 shares.
• Form 4 was signed on 2026-03-30 by attorney-in-fact.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as modestly positive due to performance award vesting and increased insider ownership, but routine in nature with limited informational value.

Positives

• Vesting of a performance award (1,184 shares) tied to the 2023–2025 cycle indicates at least threshold achievement of performance goals.
• Executive’s direct ownership increased by 703 shares to 4,851, further aligning incentives with shareholders.

Negatives

• 481 shares were withheld to satisfy taxes, reducing the net increase in holdings.
• No open-market purchase was reported, which typically provides a stronger signal of insider conviction.

Future Outlook

No forward-looking statements or guidance provided.

Industry Context

StockSavvy.ai notes that three-year performance share vesting with same-day tax withholding is standard across healthcare diagnostics peers. Similar patterns are commonly observed at Quest Diagnostics (DGX) and broader life sciences companies, and such Form 4 events are typically routine and not indicative of a strategic shift.

Comparison to Industry Standards

• Consistent with Quest Diagnostics (DGX) practices where executives receive multi-year PSU grants that vest based on performance metrics, followed by tax withholding via share surrender.
• The three-year performance period mirrors common executive compensation structures across large-cap healthcare and life sciences firms (e.g., Thermo Fisher Scientific, Danaher), where PSUs vest on cumulative performance and shares are withheld to cover taxes.
• Insider transactions tied to equity award vesting generally carry less signaling value than open-market insider buys across the sector; the reported activity aligns with routine compensation administration.

Stakeholder Impact

• Shareholders: Routine executive equity vesting with a small net increase in insider holdings (703 shares), offering limited signal value.
• Employees/Executives: Confirms payout under the 2023–2025 performance plan, supporting retention and alignment incentives.
• Investors: Updated insider ownership for the executive now totals 4,851 direct shares.

Next Steps

• No specific follow-up actions or events disclosed.

Key Dates

Keywords

Labcorp, LH, Form 4, insider transaction, performance stock units, PSU vesting, equity award, tax withholding, executive compensation, Megan D. Bailey, clinical laboratory, healthcare diagnostics